Skip to content

Study · Non-randomized trial · 1996

7 results

Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.

Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, Wass JA, Dowling RH

Gut1 May 1996Cited by 48 (Europe PMC)

PMID8707128 (opens in a new tab)PMCIDPMC1383164 (opens in a new tab)DOI10.1136/gut.38.5.775 (opens in a new tab)PepBankPUB-08707128
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In control subjects, octreotide reduced meal-stimulated gall bladder ejection fraction from 66.0 (2.3)% to 7.0 (5.3)% (p < 0.001).

    In plain wordsIn control subjects, octreotide reduced meal-stimulated gall bladder emptying compared with saline.

    Peptide
    Octreotide
    Outcome
    DecreaseGall bladder ejection fraction in controls
    Study

    n: not reported in source

    Comparator
    Saline
    Outcome group
    Gall Bladder Emptying · Gastrointestinal
    Studied dose
    50 microgramsAs given in this study (human).

    Measurements

    Gall bladder ejection fraction, starting value
    66%
    controls; mean, SEM 2.3
    Gall bladder ejection fraction after single octreotide dose
    7%
    controls; mean, SEM 5.3

    Source sentences

    Summary
    A single dose of octreotide inhibited meal stimulated gall bladder emptying, the ejection fraction falling from mean (SEM) 66.0 (2.3)% to 7.0 (5.3)% in controls (p < 0.001)
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In untreated acromegalic patients, octreotide reduced gall bladder ejection fraction from 72.5 (2.1) to 16.6 (5.1)% (p < 0.001).

    In plain wordsIn previously untreated acromegalic patients, octreotide reduced meal-stimulated gall bladder emptying compared with saline.

    Peptide
    Octreotide
    Outcome
    DecreaseGall bladder ejection fraction in untreated acromegaly
    Study

    n: not reported in source

    Comparator
    Saline
    Outcome group
    Gall Bladder Emptying · Gastrointestinal
    Studied dose
    50 microgramsAs given in this study (human).

    Measurements

    Gall bladder ejection fraction, starting value
    72.5%
    untreated acromegalic patients; mean, SEM 2.1
    Gall bladder ejection fraction after single octreotide dose
    16.6%
    untreated acromegalic patients; mean, SEM 5.1

    Source sentences

    Summary
    from 72.5 (2.1) to 16.6 (5.1)% in untreated acromegalic patients (p < 0.001)
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.
  3. 03HumanNon-randomized trialEfficacy outcome

    In controls, octreotide prolonged mouth to caecum transit from 112 (15) to 237 (13) min (p < 0.001).

    In plain wordsIn controls, octreotide prolonged mouth to caecum transit compared with saline.

    Peptide
    Octreotide
    Outcome
    IncreaseMouth to caecum transit in controls
    Study

    n: not reported in source

    Comparator
    Saline
    Outcome group
    Intestinal Transit · Gastrointestinal
    Studied dose
    50 microgramsAs given in this study (human).

    Measurements

    Mouth to caecum transit time, starting value
    112 min
    controls; mean, SEM 15
    Mouth to caecum transit time after single octreotide dose
    237 min
    controls; mean, SEM 13

    Source sentences

    Summary
    Octreotide prolonged mouth to caecum transit time, from 112 (15) min to 237 (13) min in controls (p < 0.001)
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.
  4. 04HumanNon-randomized trialEfficacy outcome

    In untreated acromegalic patients, octreotide prolonged mouth to caecum transit from 170 (13) to 282 (11) min (p < 0.001).

    In plain wordsIn previously untreated acromegalic patients, octreotide prolonged mouth to caecum transit compared with saline.

    Peptide
    Octreotide
    Outcome
    IncreaseMouth to caecum transit in untreated acromegaly
    Study

    n: not reported in source

    Comparator
    Saline
    Outcome group
    Intestinal Transit · Gastrointestinal
    Studied dose
    50 microgramsAs given in this study (human).

    Measurements

    Mouth to caecum transit time, starting value
    170 min
    untreated acromegalic patients; mean, SEM 13
    Mouth to caecum transit time after single octreotide dose
    282 min
    untreated acromegalic patients; mean, SEM 11

    Source sentences

    Summary
    from 170 (13) min to 282 (11) min in untreated acromegalic patients (p < 0.001)
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.
  5. 05HumanObservational studyEfficacy outcome

    In acromegalic patients taking long-term octreotide, gall bladder ejection fraction fell to 30.4 (9.5)% versus untreated patients (p < 0.001).

    In plain wordsIn acromegalic patients, long-term octreotide use was linked to lower gall bladder emptying than in untreated patients.

    Peptide
    Octreotide
    Outcome
    DecreaseGall bladder ejection fraction during long-term treatment
    Study

    n: not reported in source

    Comparator
    Untreated acromegalic group
    Outcome group
    Gall Bladder Emptying · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Gall bladder ejection fraction
    30.4%
    acromegalic patients taking long-term octreotide; mean, SEM 9.5

    Source sentences

    Summary
    and to 30.4 (9.5)% in acromegalic patients taking long term octreotide (p < 0.001 v untreated acromegalic group).
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.
  6. 06HumanObservational studyEfficacy outcome

    In acromegalic patients taking long-term octreotide, mouth to caecum transit increased to 247 (10) min versus untreated patients (p < 0.001).

    In plain wordsIn acromegalic patients, long-term octreotide use was linked to longer intestinal transit than in untreated patients.

    Peptide
    Octreotide
    Outcome
    IncreaseMouth to caecum transit during long-term treatment
    Study

    n: not reported in source

    Comparator
    Untreated acromegalic patients
    Outcome group
    Intestinal Transit · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Mouth to caecum transit time
    247 min
    acromegalic patients taking long-term octreotide; mean, SEM 10

    Source sentences

    Summary
    and to 247 (10) min in acromegalic patients taking long term octreotide (p < 0.001 v untreated acromegalic patients).
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.
  7. 07HumanObservational studyEfficacy outcome

    In acromegalic patients, large bowel transit was 47 (6) h with octreotide versus 40 (6) h untreated, described as unchanged.

    In plain wordsIn acromegalic patients, large bowel transit did not differ between octreotide-treated and untreated patients.

    Peptide
    Octreotide
    Outcome
    No significant changeLarge bowel transit
    Study

    n: not reported in source

    Comparator
    Octreotide-untreated acromegalic patients
    Outcome group
    Intestinal Transit · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Large bowel transit
    40 h
    acromegalic patients not treated with octreotide; mean, SEM 6
    Large bowel transit
    47 h
    acromegalic patients treated with octreotide; mean, SEM 6

    Source sentences

    Summary
    The mean large bowel transit in octreotide untreated compared with treated acromegalic patients remained unchanged (40 (6) h v 47 (6) h).
    1 context sentence
    Summary · context
    Gall bladder emptying and mouth to caecum transit was measured in (a) control subjects and acromegalic patients given saline or 50 micrograms of octreotide, and (b) acromegalic patients taking long term octreotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.